News
-
-
PRESS RELEASE
Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session
Inventiva presents positive results from Phase 2 study on lanifibranor and empagliflozin combination therapy for MASH and T2D patients at AASLD The Liver Meeting® 2024 -
-
-
-
-
-
PRESS RELEASE
Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024
Inventiva announces late breaker abstract from LEGEND Phase 2 trial evaluating lanifibranor with empagliflozin in MASH at AASLD The Liver Meeting® 2024 -
-
PRESS RELEASE
Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants
Inventiva announces the availability of a prospectus for financing through the issuance of shares and warrants. The AMF approved the prospectus on October 14, 2024
